BioSpace News Archive

The quest to change the very nature of being, has driven philosophical and metaphysical debates for ages. Now, with the advent of genome editing techniques, man is changing the very fabric of biological existence quite literally.

China Biologic Products Holdings, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that it has called an extraordinary general meeting of shareholders (the “EGM”) to be held on March 1, 2021 at 10:00 a.m. (Beijing time)

RenalSense, a leading company in real-time renal diagnostics, announced a distribution agreement with Medtechnica, Israel’s largest distributor of medical equipment and health services.

On January 24, Dow and The Nature Conservancy celebrated the 10-year milestone of their unique collaboration to demonstrate the business case for valuing nature in business decisions.

EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT ® (Siltuximab for Injection) in China

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the company held a successful Type B meeting with the U.S. Food and Drug Administration (FDA) to align with the Agency on the company’s proposal

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for odevixibat for the treatment of pruritus in patients with progressive familial intrahepatic cholestasis (PFIC)

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced strongly positive interim results of the first 64 chronic deep vein thrombosis (“DVT”) patients enrolled in the ClotTriever Outcomes Registry (“CLOUT”).

Maverick Medical AI announces the addition of Elad Benjamin to its Board of Directors. Elad brings over 20 years of executive-level experience in the Healthcare & Enterprise Software industry

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) (“BioVaxys” or “Company”) is pleased to provide a corporate update on recent advancements of its vaccine platforms, and viral diagnostic and corporate objectives for 2021